X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (230) 230
female (221) 221
oncology (177) 177
middle aged (161) 161
aged (133) 133
index medicus (133) 133
adult (126) 126
cancer (91) 91
carcinoma (75) 75
obstetrics & gynecology (67) 67
ovarian cancer (67) 67
chemotherapy (63) 63
aged, 80 and over (59) 59
surgery (54) 54
prognosis (53) 53
cervical cancer (52) 52
ovarian neoplasms - pathology (51) 51
treatment outcome (48) 48
neoplasm staging (44) 44
care and treatment (43) 43
ovarian neoplasms - drug therapy (42) 42
retrospective studies (38) 38
uterine cervical neoplasms - pathology (38) 38
antineoplastic combined chemotherapy protocols - therapeutic use (37) 37
hematology, oncology and palliative medicine (37) 37
research (35) 35
immunohistochemistry (34) 34
disease-free survival (33) 33
radiation-therapy (32) 32
radiotherapy (32) 32
survival (32) 32
obstetrics and gynecology (30) 30
hysterectomy (27) 27
analysis (26) 26
expression (26) 26
oncology, experimental (26) 26
prospective studies (26) 26
uterine cervical neoplasms - therapy (26) 26
endometrial cancer (25) 25
survival analysis (25) 25
survival rate (24) 24
tumors (24) 24
antineoplastic agents - therapeutic use (23) 23
cancer patients (23) 23
cisplatin (23) 23
endometrial neoplasms - pathology (23) 23
combined modality therapy (22) 22
follow-up studies (22) 22
lymph node excision (22) 22
uterine cervical neoplasms - drug therapy (22) 22
breast-cancer (20) 20
health aspects (20) 20
women (20) 20
feasibility studies (19) 19
lymphatic metastasis (19) 19
ovarian neoplasms - metabolism (19) 19
paclitaxel (19) 19
patients (19) 19
time factors (19) 19
chemoradiation (18) 18
multivariate analysis (18) 18
ovarian neoplasms - mortality (18) 18
pharmacology & pharmacy (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (17) 17
carcinoma, squamous cell - pathology (17) 17
disease progression (17) 17
laparoscopy (17) 17
neoadjuvant therapy (17) 17
ovarian neoplasms - surgery (17) 17
clinical trials (16) 16
neoadjuvant chemotherapy (16) 16
quality of life (16) 16
trial (16) 16
uterine cervical neoplasms - surgery (16) 16
cancer research (15) 15
cancer therapies (15) 15
chemoradiotherapy (15) 15
cisplatin - administration & dosage (15) 15
metastasis (15) 15
radiology, nuclear medicine & medical imaging (15) 15
therapy (15) 15
uterine cervical neoplasms - radiotherapy (15) 15
young adult (15) 15
gene expression regulation, neoplastic (14) 14
prognostic-significance (14) 14
radical surgery (14) 14
recurrence (14) 14
animals (13) 13
brachytherapy (13) 13
breast cancer (13) 13
cell line, tumor (13) 13
concurrent chemotherapy (13) 13
endometrial neoplasms - surgery (13) 13
medicine & public health (13) 13
paclitaxel - administration & dosage (13) 13
radical hysterectomy (13) 13
receptors, estrogen - analysis (13) 13
risk factors (13) 13
carboplatin (12) 12
complications (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2012, Volume 126, Issue 1, pp. 167 - 168
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 396 - 405
Journal Article
Current Pharmaceutical Design, ISSN 1381-6128, 06/2012, Volume 18, Issue 19, p. 2671
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 5/2014, Volume 21, Issue 5, pp. 1692 - 1699
Journal Article
BMC Cancer, ISSN 1471-2407, 02/2013, Volume 13, Issue 1, p. 72
Background: MicroRNAs in solid malignancies can behave as predictors of either good or poor outcome. This is the case with members of the miR-200 family, which... 
Class III beta-tubulin | HuR | Predictive biomarkers | MiR-200c | Ovarian cancer | miR-200c | MARKER | SENSITIVITY | HYPOXIA | PACLITAXEL | ONCOLOGY | RESISTANCE | EXPRESSION | BINDING | III BETA-TUBULIN | Immunohistochemistry | Multivariate Analysis | Adenocarcinoma - pathology | Immunoprecipitation | Paclitaxel - pharmacology | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Cytoplasm - metabolism | Drug Resistance, Neoplasm | MicroRNAs - metabolism | Tubulin - genetics | Ovarian Neoplasms - mortality | RNA, Messenger - metabolism | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | Tubulin - metabolism | Adenocarcinoma - metabolism | Cell Nucleus - metabolism | Transfection | RNA Interference | Time Factors | Biomarkers, Tumor - metabolism | Female | Adenocarcinoma - genetics | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | 3' Untranslated Regions | Binding Sites | Microfluidic Analytical Techniques | Adenocarcinoma - immunology | ELAV Proteins - metabolism | Kaplan-Meier Estimate | Proportional Hazards Models | Cisplatin - pharmacology | Disease-Free Survival | Glucose - deficiency | Adenocarcinoma - therapy | Cell Line, Tumor | Ovarian Neoplasms - therapy | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Nanotechnology | Adenocarcinoma - mortality | Ovarian Neoplasms - immunology
Journal Article
The Lancet Oncology, ISSN 1470-2045, 09/2018, Volume 19, Issue 9, pp. 1147 - 1149
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2011, Volume 121, Issue 2, pp. 422 - 422
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 154 - 156
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2010, Volume 28, Issue 19, pp. e321 - e322
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 83, Issue 5, pp. e627 - e631
Purpose To define the maximum tolerated dose of a conformal short-course accelerated radiotherapy in patients with symptomatic advanced pelvic cancer. Methods... 
Radiology | Hematology, Oncology and Palliative Medicine | Palliative care | Pelvic cancer | Pain | Radiotherapy | Quality of life | RTOG-8502 | RADIATION | CANCER | IRRADIATION | ONCOLOGY | DISEASE | RTOG | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Prostatic Neoplasms - radiotherapy | Radiotherapy Planning, Computer-Assisted - methods | Humans | Middle Aged | Male | Pelvic Neoplasms - radiotherapy | Rectal Neoplasms - diagnostic imaging | Urinary Bladder Neoplasms - diagnostic imaging | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Genital Neoplasms, Female - diagnostic imaging | Prostatic Neoplasms - diagnostic imaging | Dose Fractionation | Female | Rectal Neoplasms - pathology | Pelvic Neoplasms - pathology | Prostatic Neoplasms - pathology | Genital Neoplasms, Female - radiotherapy | Pelvic Neoplasms - diagnostic imaging | Rectal Neoplasms - radiotherapy | Radiation Injuries - etiology | Radiography | Maximum Tolerated Dose | Pain Measurement - methods | Urinary Bladder Neoplasms - radiotherapy | Quality of Life | Radiotherapy, Conformal - adverse effects | Aged | Genital Neoplasms, Female - pathology | Palliative Care - methods | Radiotherapy, Conformal - methods | Care and treatment | Analgesics | Nuclear radiation | Cancer | Index Medicus | PATIENTS | PAIN | NEOPLASMS | METASTASES | RADIOLOGY AND NUCLEAR MEDICINE | RADIATION DOSES | TOXICITY | RADIOTHERAPY | STANDARD OF LIVING
Journal Article
Breast Cancer: Targets and Therapy, ISSN 1179-1314, 2018, Volume 10, pp. 143 - 151
To compare late toxicity after postoperative hypofractionated radiotherapy (RT) and standard fractionated RT in patients with early-stage breast carcinoma.... 
Hypofractionation | Breast cancer | Retrospective study | Radiotherapy | Care and treatment | Cancer patients | Analysis | Oncology, Experimental | Skin | Research | Smoking | Cancer | Chemotherapy | Surgery | Oncology | Mammography | Radiation therapy | Patients | Cancer therapies | radiotherapy | breast cancer | hypofractionation | retrospective study
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.